(Q44601099)

English

Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

scientific article published on 10 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

Gavin Giovannoni

2

object named as

Gavin Giovannoni

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Eva Havrdova

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dusan Stefoski

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Samantha Forster

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Kimberly Umans

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Lahar Mehta

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Steven Greenberg

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Jacob Elkins

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

10 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

464-470

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Multiple sclerosis: an immune or neurodegenerative disorder?

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Multiple sclerosis: pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Freedom from disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Acute myocardial infarction and heart failure in acute stroke patients: frequency and influence on clinical outcome.

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Corticosteroids and plasma exchange in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study

1 reference

https://api.crossref.org/works/10.1177%2F1352458513502113

21 January 2018

Identifiers

10.1177/1352458513502113

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44601099&oldid=2029128541"